US Pharma MarketingFosun pays $60M for option on AriBio’s phase 3 Alzheimer’s asset
Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand its rights to the asset in exchange for a further $80 million. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation…
Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand its rights to the asset in exchange for a further $80 million.
Source: FierceBiotech